Nevro Corp.
Nevro Corp. (NVRO) Financial Performance & Income Statement Overview
Analyze Nevro Corp. (NVRO) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Nevro Corp. (NVRO) Income Statement & Financial Overview
View the income breakdown for Nevro Corp. NVRO across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $105.55M | $96.91M | $104.16M | $101.90M |
| Cost of Revenue | $39.63M | $32.30M | $36.69M | $34.34M |
| Gross Profit | $65.92M | $64.61M | $67.47M | $67.56M |
| Gross Profit Ratio | $0.62 | $0.67 | $0.65 | $0.66 |
| R&D Expenses | $11.99M | $10.58M | $14.12M | $14.83M |
| SG&A Expenses | $76.20M | $68.47M | $76.77M | $85.09M |
| Operating Expenses | $117.33M | $78.48M | $92.59M | $99.92M |
| Total Costs & Expenses | $156.96M | $110.78M | $129.28M | $134.26M |
| Interest Income | $2.98M | $3.23M | $3.32M | $3.78M |
| Interest Expense | $6.63M | $7.008M | $6.74M | $6.51M |
| Depreciation & Amortization | $3.30M | $3.27M | $3.57M | $3.97M |
| EBITDA | -$43.01M | -$4.79M | -$9.001M | -$14.55M |
| EBITDA Ratio | -$0.41 | -$0.05 | -$0.09 | -$0.14 |
| Operating Income | -$51.41M | -$13.87M | -$25.12M | -$32.36M |
| Operating Income Ratio | -$0.49 | -$0.14 | -$0.24 | -$0.32 |
| Other Income/Expenses (Net) | -$1.53M | -$1.20M | $5.81M | $7.34M |
| Income Before Tax | -$52.94M | -$15.06M | -$19.31M | -$25.03M |
| Income Before Tax Ratio | -$0.50 | -$0.16 | -$0.19 | -$0.25 |
| Income Tax Expense | $169000.00 | $280000.00 | $262000.00 | $382000.00 |
| Net Income | -$53.11M | -$15.34M | -$19.57M | -$25.41M |
| Net Income Ratio | -$0.50 | -$0.16 | -$0.19 | -$0.25 |
| EPS | -$1.41 | -$0.41 | -$0.53 | -$0.70 |
| Diluted EPS | -$1.41 | -$0.41 | -$0.53 | -$0.70 |
| Weighted Avg Shares Outstanding | $37.62M | $37.32M | $36.94M | $36.47M |
| Weighted Avg Shares Outstanding (Diluted) | $37.62M | $37.32M | $36.94M | $36.47M |
Over the past four quarters, Nevro Corp. demonstrated steady revenue growth, increasing from $101.90M in Q1 2024 to $105.55M in Q4 2024. Operating income reached -$51.41M in Q4 2024, maintaining a consistent -49% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$43.01M, reflecting operational efficiency. Net income dropped to -$53.11M, with EPS at -$1.41. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan